Essential phospholipids for people with non-alcoholic fatty liver disease (Protocol)

9Citations
Citations of this article
38Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Non-alcoholic fatty liver disease (NAFLD) covers conditions related to accumulation of fat in the liver if specific causes, such as significant alcohol consumption, long-term use of a steatogenic medication, or monogenic hereditary disorders can be excluded (WGO 2014). Non-alcoholic fatty liver disease features a wide spectrum of histologically conditions, from simple accumulation of fat ('fatty liver' or hepatic steatosis) to non-alcoholic steatohepatitis (NASH), liver fibrosis, and liver cirrhosis with clinical consequences (Brunt 2011; McPherson 2015; Bertot 2016). Simple hepatic steatosis is defined as when the fat, built up in the epithelial cells of the liver, is at least 5% of the liver weight, and the parenchymal cells and liver structure are intact. Non-alcoholic fatty liver (NAFL) is defined as the presence of hepatic steatosis with no evidence of hepatocellular injury in the formof ballooning of the hepatocytes. Non-alcoholic steatohepatitis is defined as the presence of hepatic steatosis and inflammation with hepatocyte injury (ballooning) with or without fibrosis (Brunt 2011). Nonalcoholic fatty liver disease is considered to be a clinical manifestation of the metabolic syndrome, that is the co-occurrence of metabolic risk factors for both type 2 diabetes and cardiovascular disease (abdominal obesity, hyperglycaemia, dyslipidaemia, and hypertension) (Dyson 2014;Mikolasevic 2016; AASLD NAFLD 2018). The prevalence of NAFLD is increasing, but only a small number of affected people develop inflammation, which may be followed by fibrosis and cirrhosis, possibly requiring liver transplantation (Bertot 2016; Younossi 2016). The life expectancy in people with hepatic steatosis is reported to be similar to the life expectancy of the general population (Lazo 2011).

Cite

CITATION STYLE

APA

Varganova, D. L., Pavlov, C. S., Casazza, G., Nikolova, D., & Gluud, C. (2019). Essential phospholipids for people with non-alcoholic fatty liver disease (Protocol). Cochrane Database of Systematic Reviews, 2019(4). https://doi.org/10.1002/14651858.CD013301

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free